Pancreatic cancer is the fourth leading cause of cancer-related mortality in the United States, and 80% -85% of patients have incurable disease at the time of diagnosis. Furthermore, more than 95% of patients diagnosed with pancreatic cancer will ultimately die from the disease, highlighting the urgent need for novel insights into pancreatic tumorigenesis.
Defining Determinants of Pancreatic Cancer Risk: Are We Making Progress?
Brian M. Wolpin , Meir J. Stampfer current study (6) , they work to extend this fi nding and demonstrate a modest increase in risk among those participants who consumed total fat, saturated fat, and monounsaturated fat in the highest vs the lowest quintile, with multivariable-adjusted hazard ratios between 1.2 and 1.4. Interestingly, only fatty acids from animal sources were statistically signifi cantly associated with risk.
The study by Thiébaut et al. (6) has several notable and important strengths. The large base population leads to an impressively large number of pancreatic cancer cases available for analysis. The prospective design of the study without the need for proxy respondents increases the interpretability of the results, by limiting the potential for bias and misclassifi cation. The data collected on dietary habits were suffi ciently detailed to capture information on the diversity of food products, such as "low-fat" versions of foods, and nicely demonstrate the utility of well-designed food-frequency questionnaires in prospective studies of diet and cancer.
Overall, this well-performed prospective cohort study is a welcome addition to our understanding of a disease that is in great need of new insights. However, the available epidemiological and laboratory evidence are insuffi cient to confi rm the importance of animal fats, per se, or even that meat is the important factor, as opposed to other dietary or lifestyle preferences associated with meat consumption. Nonetheless, suffi cient evidence already suggests health benefi ts from limiting meat and saturated fat intake ( 8 ) , and the current study provides additional support for these recommendations. Also, with further investigation, this work has the potential to provide interesting clues to the mechanisms underlying pancreatic tumorigenesis.
Although large prospective cohort studies with questionnairebased analyses will continue to have much to offer in defi ning predisposing factors for diffi cult diseases, such as pancreatic cancer, how can we move beyond what has been done before? Two principles are worth mentioning: increased collaboration and greater use of participant-derived biological samples. Because of the relatively low incidence rate of pancreatic cancer, collaboration is vital to provide the critical mass of cases for meaningful analyses. Second, there is great potential for well-designed studies using banked plasma, germline DNA, and tumor tissue samples to advance our understanding of pancreatic cancer pathogenesis.
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Evidence of this potential is clearly visible in studies of other malignancies, such as colon ( 9 ) and breast ( 10 ) cancer, and in the work linking prediagnostic insulin resistance with pancreatic cancer risk ( 11 , 12 ) . In the realm of pancreatic cancer research, a laudable example of this approach is the Pancreatic Cancer Cohort Consortium, a collaborative effort of 12 prospective cohort studies working to identify novel risk markers for pancreatic cancer. The results of this collaboration and others similar to it are likely to push our research efforts in novel directions and provide hope for meaningful progress in this highly lethal disease.
